Skip to main content

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

Active, not recruiting · NCT02130362

Conditions: Crohn's Disease

At a glance

Research payments reported, 2025
$113,955
U.S. investigators named
29
Sites paid
28
Planned or actual enrollment
1,446

About the trial

Sponsor
AbbVie
Dates
Started 2014-08-28; completion 2030-11
Results posted
Not yet

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.

From ClinicalTrials.gov, last updated 2025-07-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $113,955 in research payments for this study in 2025 (69 payments).

Products named: Humira, Rinvoq

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.